Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program

Gottlieb, AB; Burge, R; Malatestinic, WN; Zhu, BJ; Zhao, YY; McCormack, J; Kimel, M; Merola, JF

Gottlieb, AB (通讯作者)，Icahn Sch Med Mt Sinai, New York, NY 10029 USA.

DERMATOLOGY AND THERAPY, 2023; 13 (8): 1831

Abstract

IntroductionIxekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) i......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索